BACKGROUND: Despite recent therapeutic advances in chronic lymphocytic leukemia (CLL), access to innovative treatments may still be uneven outside Western Europe. This study aimed to explore reimbursement policy and access to novel targeted CLL therapies across selected countries and to analyze factors associated with differences in treatment availability and reimbursement timelines. METHODS: Reimbursement frameworks, timelines, and accessibility of six novel CLL therapies were assessed across 15 countries in Central and Eastern Europe, the Balkans, Armenia, and Israel. Data were collected via expert surveys in late 2024, based on publicly available national and regional sources. The survey covered reimbursement extent, timelines, policy restrictions, coverage pathways, and health technology assessment (HTA) evaluations. Comparative analyses examined regional differences in reimbursement and their potential drivers. Spearman's rank correlation was used to explore associations between the number of reimbursed therapies, reimbursement delays, and demographic, macroeconomic, and epidemiological variables. RESULTS: The number of reimbursed therapies ranged from zero (Ukraine, Armenia) to five (Czech Republic), with a regional mean of 2.7 (SD = 1.38) and overall mean time to reimbursement of 29.3 months (SD = 21.4). Ibrutinib, reimbursed in 13 countries, had the longest mean reimbursement delay (35.6 months), while venetoclax (11 countries, 26.5 months), acalabrutinib (9 countries, 16.4 months), and zanubrutinib (6 countries, 15.2 months) had shorter delays. Gross domestic product (GPD) per capita showed a moderate positive correlation with the number of reimbursed therapies (ρ = 0.673, p = 0.006). Borderline significant associations were noted for CLL incidence and mortality (p = 0.050). Reimbursement indications were often restricted, particularly for patients without deletion 17p or TP53 mutations who experienced late relapses. Data on HTA outcomes and the number of treated patients were limited in several countries, and common challenges included funding constraints, administrative barriers, and the lack of centralized rare disease policies. CONCLUSION: Significant disparities in access to targeted CLL therapies persist across the analyzed countries, with the number of reimbursed therapies positively correlated with GDP per capita.

Agency for Medicinal Products and Medical Devices Zagreb Croatia

Agency for Medicines and Medical Devices of Bosnia and Herzegovina Sarajevo Bosnia and Herzegovina

Department of Nutrition and Drug Research Faculty of Health Sciences Jagiellonian University Medical College Cracow Poland

Department of Organization and Economics of Pharmacy Faculty of Pharmacy Medical University of Sofia Sofia Bulgaria

Department of Organization and Management of Pharmacy Faculty of Pharmacy Comenius University in Bratislava Bratislava Slovakia

Department of Pharmacology and Clinical Pharmacology Medical Faculty of the University of Montenegro University of Montenegro Podgorica Montenegro

Department of Pharmacology with Clinical Pharmacology Horbachevsky Ternopil National Medical University Ternopil Ukraine

Department of Pharmacy Faculty of Medicine University of Nis Nis Serbia

Department of Reimbursement National Health Insurance Fund Management Budapest Hungary

Doctoral School of Medical and Health Sciences Jagiellonian University Medical College Cracow Poland

EconHealth s r o Prague Czechia

Faculty of Biotechnology and Drug Development University of Rijeka Rijeka Croatia

Hungarian Health Economics Association Budapest Hungary

Institute of Family Medicine and Public Health University of Tartu Tartu Estonia

Medison Pharma Petah Tiqva Israel

Pharmacy and Pharmacology Center Faculty of Medicine Vilnius University Vilnius Lithuania

Romanian Association of International Medicine Manufacturers Bucharest Romania

Yerevan State Medical University Yerevan Armenia

Zobrazit více v PubMed

Byrd J. C., Brown J. R., O’Brien S., Barrientos J. C., Kay N. E., Reddy N. M., et al. (2014). Ibrutinib PubMed DOI PMC

Eichhorst B., Robak T., Montserrat E., Ghia P., Niemann C. U., Kater A. P., et al. (2021). Chronic lymphocytic leukaemia: ESMO clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 32, 23–33. 10.1016/j.annonc.2020.09.019 PubMed DOI

Fernandez J., De Boissieu P., Galbraith M. (2025). Health technology assessment in Europe: a comparison of organizations and introduction to the European regulation. La Presse Médicale 54, 104282. 10.1016/j.lpm.2025.104282 PubMed DOI

Hofmarcher T., Berchet C., Dedet G. (2024). Access to oncology medicines in EU and OECD countries. OECD Health Working Papers, No. 170 (Paris: OECD Publishing). 10.1787/c263c014-en DOI

Holasová J., Wild A., Hrubiško M. (2025). Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia – real-world data from a hemato-oncology center. neo 72, 137–143. 10.4149/neo_2025_241211n518 PubMed DOI

Institute for Health Metrics and Evaluation (IHME) (2022). Global Burden of Disease Study 2021 (GBD 2021) results. Available online at: https://vizhub.healthdata.org/gbd-results/.

Iskierka-Jażdżewska E., Puła B., Szeremet A., Hus M., Gołos A., Hołojda J., et al. (2019). Ibrutinib discontinuation in patients with relapsed or refractorychronic lymphocytic leukemia treated in acompassionate use program:a report from the Polish Adult Leukemia Study Group (PALG). Adv. Clin. Exp. Med. 28, 1051–1057. 10.17219/acem/99911 PubMed DOI

Jakubowski S., Kawalec P., Holko P., Kowalska-Bobko I., Kamusheva M., Petrova G., et al. (2024). Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries. Front. Pharmacol. 15, 1369178. 10.3389/fphar.2024.1369178 PubMed DOI PMC

Kater A. P., Seymour J. F., Hillmen P., Eichhorst B., Langerak A. W., Owen C., et al. (2019). Fixed duration of Venetoclax-Rituximab in Relapsed/Refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: Post-Treatment Follow-Up of the MURANO phase III Study. JCO 37, 269–277. 10.1200/JCO.18.01580 PubMed DOI

Kawalec P., Tesar T., Vostalova L., Draganic P., Manova M., Savova A., et al. (2017). Pharmaceutical regulation in central and Eastern European countries: a Current review. Front. Pharmacol. 8, 892. 10.3389/fphar.2017.00892 PubMed DOI PMC

Löblová O., Csanádi M., Ozierański P., Kaló Z., King L., McKee M. (2019). Patterns of alternative access: unpacking the Slovak extraordinary drug reimbursement regime 2012-2016. Health Policy 123, 713–720. 10.1016/j.healthpol.2019.05.021 PubMed DOI

Malinowski K. P., Kawalec P., Trabka W., Sowada C., Pilc A. (2018). Reimbursement of orphan drugs in Europe in relation to the type of authorization by the European Medicines Agency and the decision making based on health technology assessment. Front. Pharmacol. 9, 1263. 10.3389/fphar.2018.01263 PubMed DOI PMC

Mato A. R., Davids M. S., Sharman J., Roeker L. E., Kay N., Kater A. P., et al. (2022). Recognizing unmet need in the era of targeted therapy for CLL/SLL: “what’s Past Is Prologue” (Shakespeare). Clin. Cancer Res. 28, 603–608. 10.1158/1078-0432.CCR-21-1237 PubMed DOI PMC

Moldovianu A.-M., Stoia R., Vasilica M., Ursuleac I., Badelita S. N., Tomescu A. A., et al. (2023). Real-World clinical outcomes and adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib: a single-center retrospective Study. Medicina 59, 324. 10.3390/medicina59020324 PubMed DOI PMC

Monica M., Reczek M., Kawalec P. (2024a). Comparative safety of novel targeted therapies in relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis. Ther. Adv. Med. Oncol. 16, 17588359241285988. 10.1177/17588359241285988 PubMed DOI PMC

Monica M., Reczek M., Kawalec P. (2024b). Network meta-analysis of novel targeted therapies for relapsed/refractory chronic lymphocytic leukemia. Ther. Adv. Med. Oncol. 16, 17588359241263710. 10.1177/17588359241263710 PubMed DOI PMC

Mukkamalla S. K. R., Taneja A., Malipeddi D., Master S. R. (2025). Chronic lymphocytic leukemia,” in PubMed

Munir T., Brown J., O’Brien S., Barrientos J. C., Barr P. M., Reddy N. M., et al. (2019). Final analysis from RESONATE: up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am. J. Hematol. 94, 1353–1363. 10.1002/ajh.25638 PubMed DOI PMC

Ou Y., Long Y., Ji L., Zhan Y., Qiao T., Wang X., et al. (2022). Trends in disease burden of chronic lymphocytic leukemia at the global, regional, and national levels from 1990 to 2019, and projections until 2030: a population-based epidemiologic Study. Front. Oncol. 12, 840616. 10.3389/fonc.2022.840616 PubMed DOI PMC

SEER (2024). Cancer stat facts: leukemia — chronic Lymphocytic Leukemia (CLL). Available online at: https://seer.cancer.gov/statfacts/html/clyl.html.

Seymour J. F., Kipps T. J., Eichhorst B., Hillmen P., D’Rozario J., Assouline S., et al. (2018). Venetoclax-Rituximab in relapsed or refractory chronic lymphocytic leukemia. N. Engl. J. Med. 378, 1107–1120. 10.1056/NEJMoa1713976 PubMed DOI

Siegel R. L., Miller K. D., Fuchs H. E., Jemal A. (2021). Cancer Statistics, 2021. CA A Cancer J. Clin. 71, 7–33. 10.3322/caac.21654 PubMed DOI

Soboń A., Drozd-Sokołowska J., Paszkiewicz-Kozik E., Popławska L., Morawska M., Tryc-Szponder J., et al. (2023). Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia—a real-world analysis of the Polish Adult Leukemia Study Group. Ann. Hematol. 102, 2119–2126. 10.1007/s00277-023-05304-4 PubMed DOI PMC

Špaček M., Smolej L., Šimkovič M., Nekvindová L., Křístková Z., Brychtová Y., et al. (2023). Idelalisib plus rituximab PubMed DOI

World Bank Group (2021). World Bank open data. Available online at: https://data.worldbank.org/(Accessed January 1, 2025).

World Health Organization (2021). World Health Organization data. Available online at: https://data.who.int/.

Zamora B., Maignen F., O’Neill P., Mestre-Ferrandiz J., Garau M. (2019). Comparing access to orphan medicinal products in Europe. Orphanet J. Rare Dis. 14, 95. 10.1186/s13023-019-1078-5 PubMed DOI PMC